Medley Medical Solutions Private Limited

medleymed.com

Medleymed seeks to reimagine healthcare for the new age - with the patient at the centre. Our vision is to harness the power of technology to orchestrate the complex healthcare value chain for the benefit of patients. As an innovative start-up, promoted by a leading IT Company and led by a young team of thinkers and doers, we operate at the cutting edge of technology and health.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

LUNAPHORE AND NUCLEAI ANNOUNCE A PARTNERSHIP TO PROVIDE AIPOWERED SPATIAL BIOLOGY ANALYSIS TO ACCELERATE DRUG DEVELOPMENT

Lunaphore and Nucleai | September 09, 2022

news image

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies. “We are thrilled to announce the partnership with Lunaphore and...

Read More

Industrial Impact

THERMO FISHER SCIENTIFIC’S LARGEST SINGLE-USE TECHNOLOGY MANUFACTURING SITE OPENS IN GREATER NASHVILLE

Thermo Fisher Scientific Inc. | August 23, 2022

news image

Thermo Fisher Scientific Inc., the world leader in serving science, opened its largest single-use technology manufacturing site in Greater Nashville. The $105 million, 400,000-square-foot facility enables the company to help meet rapidly growing demand for the bioprocessing materials needed to produce vaccines and breakthrough therapies for cancer and other diseases. This new site is part of Thermo Fisher’s $650 million multi-year investment to expand its bioprocessing production cap...

Read More

Cell and Gene Therapy

TACHYON RECEIVES IND CLEARANCE FROM FDA TO DEVELOP NOVEL KDM4 INHIBITOR TACH101 FOR ADVANCED SOLID TUMORS

Tachyon Therapeutics Inc. | August 25, 2022

news image

Tachyon Therapeutics, Inc. a private biotechnology company developing transformative cancer therapies against novel targets, today announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application to develop TACH101 for the treatment of advanced solid tumors. "The approval of this IND marks a significant milestone for the Company, as TACH101 will be the first KDM4 inhibitor to enter clinical stage. ...

Read More

Diagnostics

OXFORD BIOTHERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH IMMUNOGEN TO DEVELOP NOVEL ANTIBODY-DRUG CONJUGATES

Oxford BioTherapeutics | June 14, 2022

news image

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced a multi-year collaboration to research, develop and commercialize novel, first-in-class ADCs with ImmunoGen (IMGN), a leader in the expanding field of ADCs for the treatment of cancer. The companies will utilize ImmunoGen's linker-payload technology directed to novel targets identified via OBT's proprietary OGAP® discove...

Read More
news image

Cell and Gene Therapy

LUNAPHORE AND NUCLEAI ANNOUNCE A PARTNERSHIP TO PROVIDE AIPOWERED SPATIAL BIOLOGY ANALYSIS TO ACCELERATE DRUG DEVELOPMENT

Lunaphore and Nucleai | September 09, 2022

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies. “We are thrilled to announce the partnership with Lunaphore and...

Read More
news image

Industrial Impact

THERMO FISHER SCIENTIFIC’S LARGEST SINGLE-USE TECHNOLOGY MANUFACTURING SITE OPENS IN GREATER NASHVILLE

Thermo Fisher Scientific Inc. | August 23, 2022

Thermo Fisher Scientific Inc., the world leader in serving science, opened its largest single-use technology manufacturing site in Greater Nashville. The $105 million, 400,000-square-foot facility enables the company to help meet rapidly growing demand for the bioprocessing materials needed to produce vaccines and breakthrough therapies for cancer and other diseases. This new site is part of Thermo Fisher’s $650 million multi-year investment to expand its bioprocessing production cap...

Read More
news image

Cell and Gene Therapy

TACHYON RECEIVES IND CLEARANCE FROM FDA TO DEVELOP NOVEL KDM4 INHIBITOR TACH101 FOR ADVANCED SOLID TUMORS

Tachyon Therapeutics Inc. | August 25, 2022

Tachyon Therapeutics, Inc. a private biotechnology company developing transformative cancer therapies against novel targets, today announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application to develop TACH101 for the treatment of advanced solid tumors. "The approval of this IND marks a significant milestone for the Company, as TACH101 will be the first KDM4 inhibitor to enter clinical stage. ...

Read More
news image

Diagnostics

OXFORD BIOTHERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH IMMUNOGEN TO DEVELOP NOVEL ANTIBODY-DRUG CONJUGATES

Oxford BioTherapeutics | June 14, 2022

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced a multi-year collaboration to research, develop and commercialize novel, first-in-class ADCs with ImmunoGen (IMGN), a leader in the expanding field of ADCs for the treatment of cancer. The companies will utilize ImmunoGen's linker-payload technology directed to novel targets identified via OBT's proprietary OGAP® discove...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us